Answers are grounded in this paper and cite their sources.
Conspectus Metabolite structural characterization and annotation remain major challenges in mass spectrometry-based metabolomics. High-resolution mass spectrometry has greatly expanded metabolome coverage and sensitivity, but mass spectrometry alone often cannot distinguish isobaric and isomeric metabolites, particularly stereoisomers. Ion mobility–mass spectrometry (IM–MS) addresses this limitation by adding an orthogonal gas-phase separation dimension, in which differences in molecular size, shape, and conformation are translated into measurable differences in ion mobility. Importantly, collision cross-section (CCS) derived from ion mobility provides a quantitative molecular descriptor that complements mass-to-charge (m/z) ratio, retention time, and MS/MS information for metabolite characterization and annotation. In this Account, we describe the evolution of IM–MS from an additional separation dimension toward a unique technology for gas-phase structural characterization of complex metabolome. We first examine conventional and emerging ion mobility technologies that enhance gas-phase resolving power and enable the separation of structurally related metabolites and isomers. We then discuss CCS measurement, experimental databases, computational prediction, and chemical derivatization strategies that extend ion mobility-based structural characterization to increasingly complex and challenging metabolite isomers. As the dimensionality of liquid chromatography (LC)–IM–MS increases, computational strategies are developed to preserve and integrate m/z, retention time, CCS, and MS/MS information rather than reducing mobility data to conventional features. Finally, we examine the extension of IM–MS to spatial metabolomics, where ion mobility-resolved structural information is integrated with metabolite localization across tissues. We further discuss its application to single-cell metabolomics, where IM–MS enables the resolution of molecular heterogeneity at the single-cell level. Looking forward, establishing CCS as a standardized and transferable structural descriptor, while balancing resolving power, acquisition speed, and metabolome coverage, will be critical for the continued advancement of IM–MS. Integrating multidimensional IM–MS data with emerging artificial intelligence (AI) approaches may further improve evidence-based structural annotation. Ultimately, IM–MS has the potential to shift metabolomics from detecting more molecular features toward defining molecular structures in their biological context.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: